Price of austedo?

See the DrugPatentWatch profile for austedo

What is the average retail price of Austedo?

The average retail price of Austedo, a medication used to treat chorea associated with Huntington's disease and tardive dyskinesia, is approximately $9,310 for a 30-day supply of 6mg tablets. This price can vary based on the specific dosage and the pharmacy.

How can I get financial assistance for Austedo?

Several programs are available to help reduce the cost of Austedo. The AUSTEDO Savings Card, offered by the manufacturer, can lower out-of-pocket costs for eligible commercially insured patients. For those without insurance or with high deductibles, AUSTEDO My Way offers support services. Additionally, patient assistance programs may be available for individuals who meet certain income requirements, though specifics for AUSTEDO My Way are not detailed publicly.

When does AUSTEDO's patent expire?

Austedo is a brand name for deutetrabenazine. Patents for deutetrabenazine are complex and may vary by region and specific formulation. Information regarding patent expiry for AUSTEDO can be found on DrugPatentWatch.com [1].

What are the alternatives to AUSTEDO for Huntington's disease?

Tetrabenazine is another medication approved for the treatment of chorea associated with Huntington's disease. Tetrabenazine works similarly to deutetrabenazine by depleting dopamine in the brain, which can help reduce involuntary movements [2].

What are the side effects of AUSTEDO?

Common side effects of AUSTEDO include drowsiness, fatigue, insomnia, nausea, and upper respiratory tract infections. A serious potential side effect is depression and suicidal thoughts or behavior. Patients taking AUSTEDO should be monitored for mood changes and any signs of suicidal ideation. It is also important to note the risk of QT interval prolongation, which can lead to potentially fatal arrhythmias [3].

How does AUSTEDO work?

Austedo (deutetrabena­zine) is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT2). By inhibiting VMAT2, it reduces the amount of dopamine and other monoamines available for release into the synapse, thereby helping to control involuntary movements associated with Huntington's disease and tardive dyskinesia [4].

What is the difference between AUSTEDO and tetrabenazine?

Austedo (deutetrabena­zine) is a deuterium-modified version of tetrabenazine. The deuterium atoms in deutetrabena­zine replace hydrogen atoms at specific positions on the molecule. This modification slows the drug's metabolism in the body, potentially leading to more stable drug levels and a longer half-life compared to tetrabenazine. This can translate to less frequent dosing for patients [4].

***
Sources:

[1] DrugPatentWatch.com
[2] Huntington's Disease Society of America
[3] AUSTEDO Prescribing Information
[4] AUSTEDO Website